Cite
APA Citation
Nash, P., Kirkham, B., Okada, M., Rahman, P., Combe, B., Burmester, G., Adams, D. H., Kerr, L., Lee, C., Shuler, C. L., Genovese, M., & , (2017). ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet, 389(10086), 2317–2327. http://access.bl.uk/ark:/81055/vdc_100046742420.0x000062